MapLight Therapeutics, Inc. Common Stock (MPLT) - Total Assets
Based on the latest financial reports, MapLight Therapeutics, Inc. Common Stock (MPLT) holds total assets worth $479.51 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See MapLight Therapeutics, Inc. Common Stock (MPLT) balance sheet quality index to measure how much of total assets are equity-financed.
MapLight Therapeutics, Inc. Common Stock - Total Assets Trend (2022–2025)
This chart illustrates how MapLight Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of MapLight Therapeutics, Inc. Common Stock to see how much of total assets are deployed in long-term investments.
MapLight Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
MapLight Therapeutics, Inc. Common Stock's total assets of $479.51 Million consist of 67.7% current assets and 32.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how MapLight Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MapLight Therapeutics, Inc. Common Stock (MPLT) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MapLight Therapeutics, Inc. Common Stock's current assets represent 67.7% of total assets in 2025, a decrease from 81.3% in 2022.
- Cash Position: Cash and equivalents constituted 9.8% of total assets in 2025, down from 70.2% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
MapLight Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of MapLight Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
MapLight Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 20.01 | 7.20 | 12.72 |
| Quick Ratio | 20.01 | 7.20 | 12.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $308.44 Million | $98.68 Million | $169.44 Million |
MapLight Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between MapLight Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.66 |
| Latest Market Cap to Assets Ratio | 2.43 |
| Asset Growth Rate (YoY) | 250.2% |
| Total Assets | $479.51 Million |
| Market Capitalization | $1.17 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values MapLight Therapeutics, Inc. Common Stock's assets at a significant premium (2.43x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: MapLight Therapeutics, Inc. Common Stock's assets grew by 250.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for MapLight Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of MapLight Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $479.51 Million | +250.22% |
| 2024-12-31 | $136.92 Million | +49.78% |
| 2023-12-31 | $91.41 Million | +132.07% |
| 2022-12-31 | $39.39 Million | -- |
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrit… Read more